LONDON, ONTARIO – A new study from Lawson Health Research Institute, Western University and University of Alberta suggests that COVID-19 affects the human body’s blood concentration levels of specific metabolites – small molecules broken down in the human body through the process of metabolism. Three specific metabolites identified in this study could act as biomarkers and one day be measured through an inexpensive blood test to quickly screen patients for the disease and predict which patients will become most critically ill. The team also suspects those metabolites depleted by the virus could be delivered to patients as dietary supplements, acting as a secondary therapy. Published in Critical Care Explorations, the early findings add to the research team’s growing body of evidence on the bodily changes caused by the SARS-CoV-2 virus.
“As the second wave progresses and COVID-19 cases rise, there is an overwhelming demand for testing,” says Dr. Douglas Fraser, lead researcher from Lawson and Western’s Schulich School of Medicine & Dentistry, and Critical Care Physician at London Health Sciences Centre (LHSC). “While our findings need to be confirmed in a larger group of patients, they could lead to a rapid, cost-effective screening tool as a first line of testing in the community and in-hospital.”
The study was conducted by performing metabolomics profiling on blood samples from 30 participants at LHSC: 10 COVID-19 patients and 10 patients with other infections admitted to LHSC’s ICU, as well as 10 healthy control participants. Samples were sent to The Metabolomics Innovation Centre (TMIC) at University of Alberta where a team measured plasma concentrations of 162 metabolites.
“Metabolites are the final breakdown products in the human body and play key roles in cellular activity and physiology. By studying them, we can understand chemical processes that are occurring at any given moment, including those that regulate biological functions related to health and disease,” explains Dr. David Wishart, Codirector of TMIC and Professor of Biological Sciences, Computing Science and Laboratory Medicine & Pathology with the University of Alberta. “Because the human metabolome responds very quickly to environmental factors like pathogens, metabolomics can play an important role in early-stage disease detection, including for COVID-19.”
The team discovered four metabolites of importance to COVID-19 disease detection. The concentration of one metabolite called kynurenine was elevated in COVID-19 patients while concentrations of the other three metabolites (arginine, sarcosine and lysophosphatidylcholines) were decreased. After further analysis, they discovered that by studying the concentrations of only two metabolites – kynurenine and arginine – they could distinguish COVID-19 patients from healthy participants and other critically ill patients with 98 per cent accuracy.
The team also discovered that concentrations of two metabolites (creatinine and arginine) could be used to predict which critically-ill COVID-19 patients were most at risk of dying. When measured on a patient’s first and third day in ICU, these metabolites predicted COVID-19-associated death with 100 per cent accuracy.
“It’s our hope these findings can be validated in larger patient populations and then used to develop a simple blood test that shows high likelihood of infection and disease severity, providing rapid results in as little as 20 minutes,” explains Dr. Fraser. “This could ease the demand for current testing methods, perhaps being used as a portable, first-line screening tool in the community and for when undiagnosed patients present to hospital.”
The team also notes the reduction of key metabolites reflects changes to biochemical pathways or functions in the body which are important to maintaining health and fighting disease. They suggest their findings warrant further study to determine whether certain metabolites could be boosted through dietary supplements. A precision health approach like this could lead to repaired biochemical pathways and improved disease outcomes.
“Providing dietary supplements could be a simple adjunctive or secondary therapy with meaningful outcomes,” says Dr. Fraser. “For example, the metabolite arginine is essential to tissue repair while the metabolite sarcosine activates a process to remove damaged cells. Knowing that COVID-19 causes hyperinflammation that can damage cells and tissue, particularly in the lungs, supporting these processes may prove critical.”
In an earlier study, the team was the first to profile the body’s immune response to the SARS-CoV-2 virus and discover six potential therapeutic targets to improve outcomes. In other studies, they have discovered additional biomarkers that could be used to predict how severely ill a COVID-19 patient will become and uncovered a mechanism causing blood clots in COVID-19 patients and potential ways to treat them.
“We’re working to uncover hard evidence about how the virus invades the body. Ultimately, we hope our combined findings can lead to faster diagnosis, ways to identify patients most at risk of poor outcomes and targets for novel treatments,” notes Dr. Fraser.
This study was made possible through generous donor support. London Health Sciences Foundation is the lead funder with an investment of $90,800 through a significant estate donation and existing funds. Additional funding came from Lawson, Western and the AMOSO Innovation Fund.
DOWNLOADABLE MEDIA: Photos are available on Lawson Health Research Institute’s website.
MEDIA CONTACT: Robert DeLaet Communications and External Relations Lawson Health Research Institute t. 519.685.8500 ext. 75664 c. 519.619.3872 email@example.com
ABOUT LAWSON HEALTH RESEARCH INSTITUTE
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world.
ABOUT SCHULICH SCHOOL OF MEDICINE & DENTISTRY
The Schulich School of Medicine & Dentistry at Western University is one of Canada’s preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.
ABOUT UNIVERSITY OF ALBERTA
The University of Alberta in Edmonton is one of Canada’s top teaching and research universities, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering and health sciences. Great ideas change the world, but ideas need a push forward. At the University of Alberta, we know that push has never been more important as we do our part to keep doors of opportunity open to all. We’re making research discoveries. We’re cultivating entrepreneurs. And we’re giving our students the knowledge and skills they need to turn today’s ideas into tomorrow’s innovations.
ABOUT THE METABOLOMICS INNOVATION CENTRE (TMIC)
TMIC is a nationally funded core facility which provides cutting edge metabolomics technologies, service and data resources to the research community. TMIC’s unique combination of infrastructure and scientific expertise allow for a wide range of tools for comprehensive and targeted metabolomics studies. For more information, visit http://www.metabolomicscentre.ca.
Media Contact Robert DeLaet firstname.lastname@example.org
For weekend reading, Gary Alexander, senior writer at Navellier & Associates, offers the following commentary:
Come mothers and fathers throughout the land
And don’t criticize what you can’t understand
Your sons and your daughters are beyond your command
Your old road is rapidly aging… For the times they are a-changing
– Bob Dylan, 1963
Bob Dylan turned 82 this week, and I guess he’s a little old fashioned now, too, since he recorded an album of Sinatra standards in 2015 (“Shadows in the Night”) and a Christmas carols album in 2009.
The times are changing in the employment market, too. Work has almost become a four-letter word…
Suzy Welch, 62, a Baby Boomer professor of management practice at NYU’s Stern School of Business and co-author with her late husband Jack of several best-selling business books, wrote a fascinating Op-Ed column in The Wall Street Journal last week (“For Gen Z, Unemployment Can Be a Blast, May 18, 2023).
She introduced her latest batch of “bright and shiny young MBA students” who spoke of their lazy, hazy plans after graduation: “I’ll work when I work. Until then, I’ll just do some funemployment.”
Ms. Welch said she “literally screamed in class” the first time she heard that word, shouting, “What, what, what? Are you literally saying ‘funemployment’ – like unemployment can be fun?” The class then “burst into laughter.”
Yes, of course that’s what they meant, but they were trying to keep that word secret from the older generation of up-tight Baby Boom professors, since those draft-dodging, dope-smoking hippies of the Vietnam era had now become like their parents – and their students didn’t trust anyone over 30!
For those young ones who still want to work, the older employers must also watch their step, since the old hierarchical order at work is mostly dead, if not buried. In his new book, “Generation Why” (released this month), Dr. Karl Moore of Montreal’s McGill University speaks of the new workplace rules, which sound like no rules – a dangerous minefield for managers. In his introduction, Moore makes three points.
There are three basic changes from our (Boomer) management era:
(1)Transparency over secrecy: Young workers can discover all your faults, errors, and past mistakes by surfing the Internet, so transparency is king;
(2)Credentials no longer matter as much; an MBA is the old BA, but experience trumps degrees, so all that massive college debt may be wasted; and
(3) Introverts and quieter thinkers can now lead, not just those bombastic extroverts. By Moore’s measures, 30% to 35% of C-suite leaders are now introverts. *
*To clarify terms, “C-suite” refers to anyone with “Chief” in the title, like Chief Executive Officer, Chief Operating/Chief Financial, or Chief Managing Officer. Also, here are the generally accepted birth cohorts:
Moore has a CEO Insights course at McGill for MBAs. He also takes 30 students each year to some of the fastest growing global economies to see how they do it. He calls it the “Hot Cities of the World Tour.”
They just returned from Ghana and Ivory Coast this March. In these 12-day tours, he also has a chance to dine and talk with these 30 students (Millennials and now Gen Z kids) to probe their views.
As cohorts in two colleges in Southern California in the 1970s, Moore and I emailed over this, and he told me these tours are promoted as “Taking the Future to the Future,” meaning future business leaders go to where the world is growing fastest. Some of his previous trips were to Israel, the UAE, India, and South Africa.
In his study of young workers for this book, Moore conducted over 800 interviews with under-35 workers (and shirkers) in Canada, the U.S., Japan, and all over Europe, as well as over 750 C-suite executives. Previous to his academic career, Moore also spent 11 years working in high tech firms, so he has the advantage of being a capitalist believer and doer, not just a business critic, as is so common in academia.
In the U.S., Moore writes, over one third of workers are Millennials (age 27-42), recently surpassing Gen X as the largest component of our workforce. Globally, there are 1.8 billion Millennials, about a quarter of the world, and 86% of Millennials come from developing economies, which may determine who rules the Century. Put bluntly, will the hardest workers of the world surpass our new funemployment cohort?
How Can We Have A Recession With So Many Job Openings?
A classic warning sign of a recession ahead is an inverted yield curve, which we have endured for nearly a year now without a recession. The yield curve inverted before the last four real recessions, in 1982, 1990, 2000, and 2008.
Even with the artificial 2020 recession, caused by a forced COVID-19 lockdown, the yield curve was neutral before that recession. Today, we have the most inverted yield curve since the double-dip recessions of 1979-82, yet we still stubbornly grow our GDP each quarter since mid-2022.
It’s hard (some say impossible) to have a recession with the unemployment rate at a record low, jobs continuing to expand at a solid pace, nearly 10 million jobs going begging and wages usually outpacing prices, resulting in real wage gains. Everywhere you look, you’re likely to see “HELP NEEDED” signs.
Jobs are opening even faster: The percentage of all U.S. business owners reporting job openings that they cannot fill rose by 2 points to 45% in April — maybe because “funemployment” is still widely preferable?
The labor force participation rate remained at 62.6% in April, below the pre-pandemic reading of 63.3% in February 2020, but that rate itself was historically low. It was over 64% from 1984 to 2012, peaking in 2001, when I argue (in recent columns) that we moved from a Growth economy to a Debt economy.
Funemployment Comes Home to Roost
To close on a personal note, I’ve worked every month since April 1962, age 16, first on a paper route by car, then as a night janitor to work my way through college. I commuted to work at a desk job for nearly 40 years before moving to my late parents’ home in the San Juan Islands of Washington State to work online as an editor. I tried to match the work ethic of my parents, who worked in the Great Depression.
This week marks the date when two of our five grown grandchildren arrive to live with us for the next few months, and maybe longer, as part of their funemployment option. It’s a grandparents’ dream come true, having these wonderful young ones around us – and a great help in our old age, a win-win situation.
One says, “I don’t want to sit in an office from 9 to 5 each day.” I responded, “Neither did I, nor probably 90% of those who did it, but we felt we had to.” These kids already have online and “gig” jobs, not office jobs.
I know I’m old-fashioned about work, but (with Karl Moore) I’m learning from the youth, and I know that both of these two fine youngsters will find fulfilling jobs and careers after living with us, with the caveat that retail jobs, construction, and even janitor work aren’t careers, but training ground for showing up on time, respecting rules, learning manners, and serving customer needs. They’ll find their best work.
It’s a brave new world for old fogies. But it’s comforting to know these kids will soon be old fogies, too.
June is a pivotal month.The US debt-ceiling
political drama cast a pall over sentiment even if it did not prevent the
dollar from rallying or the S&P 500 and NASDAQ from setting new highs for
the year. It is as if the two political parties in the US are playing a game of chicken
and daring the other side to capitulate. Both sides are incentivized to take to
the brink to convince their constituents that they secured the best deal
possible. No side seems to really want to abolish the ceiling because it has
proven to be an effective lever for the opposition to win concessions over the
years. Still, a higher debt ceiling and some reduction in spending in the FY24
budget are the middle ground.
Many think that this time is different. The partisanship, they say, is so
extreme that a default is possible. They can point to severe distortions in
the T-bill market and the elevated prices to insure against a US default
(credit default swaps). Neither side can be sure it will not be blamed for a default's expected and unexpected consequences. The risk of playing
chicken is that neither driver swerves at the last minute. There are only downside scenarios in a default situation, even if it lasts for a short
term and no bond payment is missed. On the other side of the debt ceiling, bill
issuance will rise, and the Treasury will rebuild its account held at the
Federal Reserve. This could drive up short-term rates and reduce liquidity.
to fiscal policy, a monetary policy drama is also playing out. The
Federal Reserve began hiking rates in March 2022, and at the May meeting, Chair
Powell indicated that a pause was possible. Although he made it clear that it
was not a commitment, the markets saw the quarter-point move as the last. However, a combination of stronger economic data, sticky price pressures, and some hawkish comments saw the pendulum of expectation swing toward a hike at the June 13-14 meeting (60%). Moreover effective Fed funds rate (weighted average) is about 5.08%, and the
market-implied year-end effective rate is around 5.0%. It was near 4% as recently as May 4, which illustrates the extent of the interest rate adjustment. Even if the Fed
stands pat in June, we expect Chair Powell to validate market expectations that
another hike will likely be forthcoming (July).
continue to be worrisome economic signs in the US, including the inverted yield
curves, the precipitous decline in the index of Leading Economic Indicators, an
outright contraction in M2 money supply, the tightening of lending standards,
and a reduction in credit demand. However, at the same time, despite some
slowing, the labor market is strong, with an improvement in prime working-age
participation. Consumption rose by 3.7% in Q1 and appears off to a good start
in Q2, with stronger auto and retail sales in April. Supply chain disruptions
have improved, shipping costs have receded and are back within the 2019
range. The Atlanta Fed's GDP tracker sees growth of 1.9% in Q2, near the Fed's
non-inflation speed limit of 1.8% and though a bit faster than Q1 (1.3%).
drama that has unfolded is the stress on US banks. Banks with increasing low-yielding assets did not offer competitive interest rates with
prime money market funds (only invest in US government/agency paper) and the US
bill market itself. While the banking system lost deposits, several of the
largest banks reported increased net interest income. However, even after
the deposits at small banks stabilized, pressure continued on their shares.
That selling pressure seemed to be exhausting itself. June may be a pivotal
period for this drama too. Still, many regional banks are exposed to the
commercial real estate market, which is under pressure.
avoided a tragic winter energy crisis, but the drama is that inflation is
providing sticky, and the regional economy looks as if it stalled at the end of
Q1. Indeed, revisions show that the German economy contracted 0.3% in Q1
after a 0.5% contraction in Q4 22. The eurozone and UK economies expanded by
0.1% quarter-over-quarter in the year's first three months. The eurozone
and UK appear stuck in low gear, but the market is confident of quarter-point
hikes by the European Central Bank and the Bank of England in June.
Japan has a
drama of its own. The Bank of Japan is under new management, but it turns out
that its extraordinary policy was not simply a function of former Governor
Kuroda's idiosyncrasies. Several surveys of market participants saw June/July
as the likely timing of an adjustment in the policy settings. However, Governor
Ueda's call for patience suggests little sense of urgency, and some
expectations are being pushed out to the end of Q3. The recent history of
lifting interest rates or currency caps suggests a dramatic market response
even under the best circumstances. Still, the best time to
adjust the cap on the 10-year bond is when it is not being challenged. The BOJ
is the last of the central banks with a negative policy rate. This is
increasingly difficult to justify. The swaps market is not pricing in a
positive rate until early in the second half of the fiscal year, which begins
on October 1.
are always dramatic. It seems clear that US officials, including President
Biden, had recognized that bringing NATO to Russia's border was provocative.
After relatively mild responses to Russia's invasion of Georgia and the taking
of Crimea, the reaction to last year's invasion of Ukraine is a big shock to nearly
everyone. The US has led a coalition that has stymied Russia by arming Ukraine with weapons, training, money, and intelligence.
Initially, China appeared to be a net loser of Russia's invasion. NATO is stronger.
US leadership was again demonstrated. Parallels between Ukraine and Taiwan were
drawn ubiquitously. There has been a rapprochement between South Korea and Japan,
and both are boosting military spending. The US secured new bases in the
Philippines. However, China is finding its own opportunities.
Just as the
US thinks Russia is in a quagmire, China may think it has the US in one.
President Biden has cast the defense of Ukraine as the frontline of the battle
between democracy and authoritarianism. However, American public support is not
particularly strong, and continued unlimited support may become a political
issue in next year's election. Meanwhile, China has moved into the vacuum
created by the US and European sanctions. China has secured Russia into its
sphere of influence, which Beijing could not have dreamed of before the
invasion. Using the swap lines with the PBOC has allowed several developing countries to pay for imports from China. It is similar to
producer-financed sales in market economies. China is exploiting niches that the US and Europe have created purposefully or otherwise. Even taking into
account the problematic debt that has arisen from the Belt Road Initiative, it
is creating and solidifying a trade network that may be of increasing
importance to China going forward.
rise in interest rates in May made for a challenging time for risk assets.
Equity indices for developed and emerging market economies fell in May, but
there were notable exceptions. The S&P 500 and NASDAQ rallied to new highs
for the year. Germany's DAX and French CAC set record highs, while Japan's
Topix and Nikkei reached their best levels since 1990. Among emerging markets, Brazil (~6%), Chile (~4%), Poland (~3%), Hungary (~6%), Taiwan (~6%), and
South Korea (~2.3%) are notable exceptions.
market currencies mostly fell in May. The JP Morgan Emerging Market Currency
Index fell by 1.3% after slipping about 0.35% in April. It is the first
back-to-back monthly decline since a four-month drop in June through September last
year. It is essentially flat on the year. Latin American currencies continue to
stand out. They accounted for four of the top five emerging market currencies
in May: Colombia (~5.1%), Mexico (~1.9%), Peruvian sol (~1.0%), and Chile (~0.4%). The South Korean won was the exception; its 1% gain put it in
the top five.
World Currency Index, a GDP-weighted basket of the currencies belonging to the
dozen largest economies, fell by about 1.4% in May. This reflected losses of
most of the currencies against the dollar. In the BWCI, only the South Korean won
(~1%), the Mexican peso (~1.9%), and the Russian rouble (~0.3%) appreciated against
the dollar. Combined, they account for about 6% of the basket. The yen was the
weakest, losing about 3%, but the euro was not far behind with a 2.75% decline.
The Chinese yuan was third, with slightly more than a 2.1% decline.
BWCI bottomed early last November near
92.80, confirming the dollar's top. It rallied into early February to peak near
98.15. The decline into March retraced about half of the rally, while the
year's low set in late May (~95.25) is within 0.75% of a critical area. This is
consistent with our base case that while there may be some scope for additional
dollar gains, it looks limited as the interest rate adjustment also appears to be complete or nearly so. In our analysis of the different currencies below, we
have tried to quantify where the base case breaks down.
interest rate adjustment, where the market converges to the Fed rather than vice versa, and the knock-on effect of supporting the US dollar
unfolding broadly aligns with the view sketched here last month. The two-year
yield rose by around 65 bp in May to about 4.65%, the highest since mid-March.
The year-end policy rate is near 5% rather than 4.5% at the end of April. We
suspect that the interest rate adjustment is nearly complete, helped by what
will likely be slower economic growth after the rebound in Q2. The growth
profile may be almost a mirror image of 2022. Then, the economy contracted in
H1 and rebounded in H2. This year, the economy appears to have grown near trend
in H1 and looks set to slow in H2. The odds of a Fed hike on June 14 were around 65% before the Memorial Day holiday (May 29), and it is fully discounted for the July meeting. The Fed's economic projections
will be updated. The 0.4% median forecast for growth at the March meeting seems
too low and will likely be increased. At the same time, the 4.5% year-end
unemployment rate seems too high. Unemployment was at 3.4% in April. The median forecast bring
it down a bit. The debt ceiling wrangling does not put the US in the best
light, but barring an actual default, it will not have lasting impact. Outside
of the T-bill market and the credit-default swaps, investors took this peculiar
American political tradition in stride. Our working hypothesis has been that
the dollar was going to "correct" the selloff that began in early
March as the bank stress struck. In the last full week of May, the Dollar Index
exceeded the retracement target near 104.00. A move above the 104.70 area would
suggest potential back toward the 200-day moving average (~105.75) and the
March high near 106.00. A break below the 103.00 area would suggest a high may
be in place.
rates could not keep pace with the dramatic swing higher in the US. Germany's
two-year yield rose by about 20 bp in May, less than half what the US
experienced. Yet, the euro's roughly 2.75% decline in May was not only a dollar
story. The proverbial bloom came off the rose. The fact that with a combination
of preparedness and good luck (low oil/gas prices and a mild winter), the
eurozone avoided an energy crisis. The positive economic impulses carried into
February, but by the end of March, economic growth stalled, or worse. After a
second look, Germany contracted by 0.3% in Q1 (initially estimated at zero)
after a 0.5% decline in economic output in Q4 22. The European Central Bank
started later than most G10 countries to begin adjusting monetary policy, and
institutional rigidities may make price pressures more resistant. The ECB meets
on June 15 and the market is confident of a quarter-point hike that would lift
the deposit rate to 3.50%. The staff will also update its economic forecasts. The
terminal rate is seen at 3.75% in late Q3 or early Q4. On June 28, European
banks are due to pay back the ECB around 475 bln euros of loans (Targeted
Long-Term Refinancing Operations). They account for around 6% of the assets on
the ECB's balance sheet and almost 45% of the outstanding TLTRO loans. The
sheer magnitude of the maturity could prove disruptive, and some banks may look
to find replacement funding. The ECB's balance sheet has been reduced by about
3% this year and the repayment of the TLTRO would do more with a single blow. Recall
that end of the of last year, European banks returned almost 492 bln euros. The
euro overshot our $1.0735 objective. We suspect the euro's downside correction
is nearly over, but a break of the $1.0680 area may signal losses back to the
March low near $1.05. (May 26, indicative closing prices, previous in parentheses) Spot: $1.0725 ($1.1020) Median Bloomberg One-month Forecast $1.0890 ($1.0960) One-month forward
implied vol 6.8% (7.5%) Japanese
Yen: Rising US rates seemed to have dragged the greenback higher
against the Japanese yen. The gains in May took it a little through JPY140, the
highest level since the end of November, and beyond the halfway marker of the
drop from last October's high near JPY152. Just as there may be some more room
for the US 10-year yield to climb above 3.80%, there may be scope for the
dollar to rise further against the yen. The next important chart area is around
JPY142.50. Underlying price pressures in Japan continue to rise, and the
weakness of the yen only adds to the pressure on the BOJ to adjust its monetary
settings. The economy expanded by 0.4% in Q1, well above expectations, and in late
May, the government upgraded its monthly economic assessment for the first time
in ten months. Several surveys found many see a window of opportunity in June
or July for the BOJ to adjust monetary policy. Most of the speculation has
focused on yield-curve-control (YCC), which caps the 10-year yield at
0.50%. We do not think it will be abandoned entirely, and targeting a
shorter-dated yield may be considered. It could lift the overnight target rate
to zero from -0.10%. If experience is any guide, when it comes, the timing will
likely surprise, and it is bound to be disruptive. It will likely weaken the
correlation between the exchange rate and US yields. Lastly, there is much talk
about a snap election in Japan over the summer as Prime Minister Kishida looks
to secure his mandate and support for him, and the cabinet has risen recently.
He hosted the G7 summit and brandished leadership. Politically, it may be the
most opportune time before September 2024 LDP leadership contest, while the
economy is relatively strong, the stock market is near 30-year highs, and he is
Spot: JPY140.60 (JPY136.30) Median Bloomberg One-month
Forecast JPY133.45 (JPY133.05) One-month forward
JPY139.95 (JPY135.75) One-month implied vol 10.8% (9.5%) British
Pound: May was a month of two halves for sterling. In the first half of
the month, it extended its recovery off the for the year set on March 8 near
$1.1800. Sterling peaked on May 10 at around $1.2680, its best level since June
2022 and an impressive recovery from last September's record low of about $1.0350.
In the second half of May, sterling trended lower and fell back to almost $1.2300.
Our base case is that the move is nearly over, with the $1.2240 area likely to
hold back steeper losses. However, if this area goes, another cent decline is
possible in this benign view. Stubborn inflation and a firm labor market have
produced a dramatic interest rate adjustment in the UK that may lend sterling
support. The year-end policy rate is seen above 5.50%. This is a 70 bp increase
since the middle of May. The two-year and 10-year Gilt yields were mostly flat
in the first half of May and soared around 75 bp in the second half. The
10-year breakeven (the difference between the inflation-protected security and
the conventional bond) rose a little more than 10 bp in the last couple of
weeks. The Bank of England meets on June 22, the day after the May CPI is
published. The market is debating whether a 25 bp or 50 bp hike will be
delivered. We lean toward the smaller move unless the incoming data surprises.
$1.2345 ($1.2565) Median Bloomberg One-month
Forecast $1.2400 ($1.2480) One-month forward
$1.2355 ($1.2575) One-month implied vol 8.0% (7.6%) Canadian
Dollar: The Canadian dollar fell by about 0.60% against the US dollar in
May, making it the best performer in the G10. The Swiss franc was second with
twice the loss. After testing April's low (~CAD1.3300) in early May, the US
dollar recovered and set the month's high (~CAD1.3650) in late May. While interest
rate developments can help explain the broader gains in the greenback, the
exchange rate with Canada seems to be more sensitive lately to the general risk
environment (for which we use the S&P 500 as a proxy) and oil. The price of
July WTI collapsed from around $76.60 at the end of April to a little below $64
on May 4. It worked its way back up to almost $75 on May 24 before stalling.
There has been a significant interest rate adjustment in Canada over the last
few weeks. The 2-year yield rose by nearly 60 bp. At the end of April, the
market was pricing in a cut before the end of the year and now it is fully
discounting a hike. The Bank of Canada meets on June 6. The swaps market has a 33% chance of a hike and a hike is fully discounted by the end of Q3. At the end of April, a June hike was
seen as less than a 10% risk. A move above CAD1.3700 could signal a return to
this year's high set in March near CAD1.3860.
Spot: CAD1.3615 (CAD 1.3550) Median Bloomberg One-month
Forecast CAD1.3405 (CAD1.3475) One-month forward CAD1.3605 (CAD1.3540) One-month implied vol 6.0% (5.8%) Australian
Dollar: The surprising quarter-point hike by the Reserve Bank of
Australia saw the Australian dollar fray the upper end of the $0.6600-$0.6800
range that has dominated since late February. Disappointing employment data,
concerns about the pace of China's recovery, and the sharp selloff of the New
Zealand dollar (following the central bank's hike that could be the last one)
weighed on the Australian dollar. It recorded the lows for the year slightly
below $0.6500. There is little meaningful chart support ahead of $0.6400, but a
move back above $0.6600 would suggest a low is in place. The squeeze on households can e expected to increase in the coming months as mortgages taken on in the early days of the pandemic will begin to float at higher rates. The RBA meets on June
6 and there seems to be little chance of a hike, though the market is not
convinced that the tightening cycle is finished. A small hike (~15 bp) is
possible in Q3. The first estimate of Q1 GDP is due the day after the RBA meeting, but we assume officials will have some inkling. Although there is some talk of the risk of a contraction, it likely grew slowly.
Peso: Between the central bank's pause and the broader dollar's
strength, the peso fell on profit-taking after it reached a new seven-year
high in the middle of May. However, the considerations that have driven it
higher remain intact, suggesting its high is not in place. Those forces include
the attractive carry (11.25% policy rate) and a relatively low vol currency
(especially among the high-yielders), the near-shoring and friend-shoring that
has seen portfolio and direct investment inflows, and, partly related, the
healthy international position, with record exports and stronger worker
remittances. The dollar fell to almost MXN17.42 in mid-May and its bounce
stalled near MXN18.00. A break of the MXN17.60 area may signal a retest of the
lows, but in the medium term, there is potential toward MXN17.00. While
Mexico's government has not facilitated an investor-friendly environment, the
market appears to be rewarding the strong and independent central bank and
Bloomberg One-Month Forecast MXN18.1675 (MXN18.26)
Chinese Yuan: China is notoriously opaque in
terms of information and economic data. The market's general sense is that
Beijing will take more measures to ensure growth stays on track with weak price
impulses. The low CPI (0.3% year-over-year in April) is partly a function of
weak demand, but the overcapacity in some sectors, such as autos, also is
deflationary. A reduction in required reserves is possible. The expected policy
divergence is more important to investors than modest swings in China's large
and persistent trade surplus. As the dollar moved to new highs for the year in
mid-May above CNY7.00, PBOC officials expressed concern about the volatility
and one-way market. And the yuan's losses have been extended further. The next
important chart area is near CNY7.10. Still, the yuan remains correlated with
the euro and yen, and their weakness helped drag the yuan to new lows for the
year. Chinese assets may not be particularly attractive to foreign asset
managers, but the yuan is being used more to settle trade (and not just with
Russia and Hong Kong). Its share of the SWIFT messages rose to 2.3% in
April, the most in six months.
Fungi are present on the skin of around 70% of the population, without causing harm or benefit. Some fungal infections, like athlete’s foot, are minor. Others, like Candida albicans, can be deadly – especially for individuals with weakened immune systems.
In 2022, the World Health Organization released its first-ever “Fungal Priority Pathogen List,” calling for improved surveillance, public health interventions and the development of new antifungal drugs.
We are an interdisciplinary team of chemists and biologists charting a new path to tackle drug-resistant infections. We are using tiny nanoscale drills that combat harmful pathogens at the molecular level. As the traditional antimicrobial research pipeline struggles, our approach has the potential to rejuvenate the fight against these stubborn infections.
Molecular machines are synthetic compounds that rapidly rotate their components at about 3 million times per second when exposed to light. Doctors can use a light-tipped probe to activate these molecular machines to treat internal infections, or a lamp for skin infections. The light starts the machines spinning, and that rotational motion pushes them to drill through and puncture the cell’s membranes and organelles, which results in cell death.
Researchers first tested the ability of light-activated molecular machines to kill fungi in Candida albicans. This yeastlike fungus can cause life-threatening infections in immunocompromised people. Compared with conventional drugs, molecular machines killed C. albicans much faster.
Subsequent studies found that molecular machines could also kill other fungi, including molds like Aspergillus fumigatus and species of dermatophytes, the types of fungi that cause skin, scalp and nail infections. Molecular machines even eliminated fungal biofilms, which are slimy, antimicrobial-resistant communities of microorganisms that stick together on surfaces and commonly cause medical device-associated infections.
Unlike conventional antifungals, which target the fungal cell membrane or cell wall, molecular machines localize to the fungal mitochondria. Often referred to as the “powerhouses of the cell,” mitochondria produce energy to power other cellular activities. When activated with visible light, molecular machines destroy the fungal mitochondria. Once the fungal cell’s mitochondria stop working, the cell loses its energy supply and dies.
At the same time, molecular machines also disrupt the tiny pumps that remove antifungal agents from the cell, thus preventing the cell from fighting back. Because these molecular machines act by a mechanical instead of a chemical mechanism, fungi are unlikely to develop defenses against this treatment.
In lab experiments, combining light-activated molecular machines with conventional antifungal drugs also reduced the amount of fungi in C. albicans-infected worms and in pig nails infected with Trichophyton rubrum, the most common cause of athlete’s foot.
New frontiers for fighting fungal infections
These results suggest that combining molecular machines with conventional antifungals can improve existing therapies and provide new options for treating resistant fungal strains. This strategy could also help reduce the side effects of traditional antifungals, such as gastrointestinal upset and skin reactions.
In the future, researchers could use artificial intelligence to create better antifungal molecular machines. By using AI to predict how different molecular machines will interact with fungi and human cells, we can develop safer and more effective antifungal molecules that specifically kill fungi without harming healthy cells.
Antifungal molecular machines are still in the early stages of development and are not yet available for routine clinical use. However, continuing research gives hope that these machines could one day provide better treatments for fungal infections and other infectious diseases.
Ana L. Santos receives funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 843116.
Jacob Beckham receives funding from the National Science Foundation Graduate Research Fellowship Program.
James M. Tour receives funding from the Discovery Institute and the Robert A. Welch Foundation (C-2017-20190330). Rice University owns intellectual property on the use of electromagnetic (light) activation of molecular machines for the killing of cells. This intellectual property has been licensed to a company in which James M. Tour is a stockholder, although he is not an officer or director of that company.